Takeda Pharmaceutical reported a 1.7% revenue decline in FY2025 to $28.4 billion, mainly due to generic competition for its drug Vyvanse. The company is implementing a transformation program and cost-cutting measures targeting $1.3 billion in annual savings by FY2028. Takeda's future growth depends on the successful launch of three new drugs: oveporexton, rusfertide, and zasocitinib. Despite current challenges, Takeda's valuation is considered reasonable, supporting a "Buy" recommendation as the market may undervalue these upcoming assets.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Bitcoin briefly reached a three-week high near $65,600 before retreating to around $64,000, influenced by lower-than-expected US inflation data and geopolitical tensions. Ethereum also reversed from a six-week peak near $1,950, slipping below $1,900....
Bitcoin fell back to $64,000 after reaching a monthly peak of $65,500 due to profit-taking and geopolitical tensions from Iranian strikes on U.S. bases. Most altcoins also declined as bearish sentiment dominated the market, with XRP futures showing i...
Taiwan Semiconductor Manufacturing Company (TSMC) announced an additional $100 billion investment in its U.S. chip production, raising its total commitment to $265 billion. This funding will support the construction of four new fabrication plants usi...
Bitcoin price briefly rose to nearly $65,470 following softer US inflation reports, raising hopes the Federal Reserve might pause rate hikes. However, profit-taking by long-term holders and whales around the $65,000 resistance led to a pullback towar...
